The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic
Top Cited Papers
- 1 August 2006
- journal article
- review article
- Published by Elsevier in The Lancet
- Vol. 368 (9534) , 531-536
- https://doi.org/10.1016/s0140-6736(06)69162-9
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational studyBMJ, 2005
- Confronting the Emergence of Drug-Resistant HIV Type 1: Impact of Antiretroviral Therapy on Individual and Population ResistanceAIDS Research and Human Retroviruses, 2005
- Factors associated with a decrease in the prevalence of drug resistance in newly HIV-1 infected individuals in MontrealAIDS, 2004
- Decreased HIV Transmission after a Policy of Providing Free Access to Highly Active Antiretroviral Therapy in TaiwanThe Journal of Infectious Diseases, 2004
- A Tale of Two Futures: HIV and Antiretroviral Therapy in San FranciscoScience, 2000
- Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in AdultsNew England Journal of Medicine, 1999
- Antiviral effect of double and triple drug combinations amongst HIV-infected adultsAIDS, 1998
- HIV-1 and the aetiology of AIDSThe Lancet, 1993
- FEMALE TO MALE TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1: RISK FACTORS FOR SEROCONVERSION IN MENThe Lancet, 1989
- RISK FACTORS FOR SEROCONVERSION TO HUMAN IMMUNODEFICIENCY VIRUS AMONG MALE HOMOSEXUALSThe Lancet, 1987